E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
A partial seizure is a seizure which occurs in just one area of the brain. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Confirm the efficacy of levetiracetam (LEV) in reducing seizure frequency in the First Period compared to historical control as adjunctive treatment in pediatric epilepsy subjects aged 1 month to <4 years with partial seizures |
|
E.2.2 | Secondary objectives of the trial |
- Evaluate the safety and tolerability of LEV in the First Period - Evaluate the efficacy of LEV in reducing seizure frequency in the First Period compared to historical control as monotherapy - Evaluate long-term safety and tolerability of LEV in the combined First and Second Periods in pediatric epilepsy subjects aged 1 month to <4 years with partial seizures receiving long-term treatment with LEV at individualized doses - Evaluate the efficacy of LEV in the combined First and Second Periods as monotherapy or adjunctive treatment - Characterize pharmacokinetics (PK) of LEV in the First and Second Period |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Subject must have a diagnosis of epilepsy with partial onset seizures whether or not secondarily generalized - Male or female from 1 month to <4 years of age. Pre-term infants aged <1 year are to be stratified into an appropriate age category using the best estimate of their corrected gestational age - For subjects on adjunctive therapy, subject must be on a stable antiepileptic drug (AED) regimen for the Selection and Evaluation Periods of the study. Minor adjustments to the dose of current AEDs are allowed only prior to Visit 1. Monotherapy subjects must not receive AED treatment, receive temporary AED treatment, or switch an AED prior to Visit 1 - Subject weighs >=3.0 kg - Subject may have Vagal Nerve Stimulation (VNS) which has been implanted for at least 6 months prior to Visit 1; the settings must be stable for at least 2 months prior to Visit 1. Activated VNS must be counted as 1 of the 2 AEDs - Subject must have experienced at least 2 observable partial seizures, with or without secondary generalization during each 7-day period during the 2 weeks prior to Visit 1. This time period (the 2 weeks prior to Visit 1) will be referred to as the Retrospective Baseline Period. This seizure information (including type, frequency, and date) must have been recorded on a daily record card (DRC) in order to be acceptable - If epilepsy surgery has been performed prior to study entry, subjects must have a documented failed epilepsy surgery outcome at least 4 weeks prior to Visit 1 - The use of intermittent benzodiazepines, phenobarbitals, and phenytoins is allowed as long as the frequency is not greater than 1 single administration per week for at least 2 weeks prior to Visit 1 and throughout study participation. If benzodiazepines are used more than once a week, they must be considered as 1 of the AEDs |
|
E.4 | Principal exclusion criteria |
- Subject has been taking any medication (other than their concomitant AEDs) that influences the central nervous system (CNS) for which they had not been on a stable regimen for at least 1 month prior to Visit 1 - Subject is taking any medication that may interfere with the absorption, distribution, metabolism, or excretion of the concomitant AEDs or levetiracetam (LEV) during the course of the study - Subject has received any investigational medication or device within 30 days prior to Visit 1 - Subject has taken LEV prior to the study - Subjects using felbamate who have presented with clinically significant abnormalities and/or hepatic function during felbamate treatment, and subjects who are taking felbamate <1year from the date of Visit 1 - History of status epilepticus requiring hospitalization during the 30 days prior to Visit 1, except for status epilepticus occurring during the first 10 days of life - Subject has a treatable seizure etiology - Subject is on a ketogenic diet (concomitantly or within 30 days prior to Visit 1) - Subject has epilepsy secondary to progressing cerebral diseases - Subject has a current diagnosis of Rasmussen’s syndrome, Landau-Kleffner disease or Lennox-Gastaut syndrome - Clinically significant deviations from reference range values for renal function or any of the other laboratory parameters required for this study, as determined by the Investigator - Clinically significant acute or chronic illness (as determined during the physical examination or from other information available to the Investigator) - Allergy to pyrrolidine derivatives or a history of multiple drug allergies - Subject is known to have a terminal illness - Subject has a disorder or condition that may interfere with the absorption, distribution, metabolism, or excretion of medications - Subject has a history of or presence of pseudoseizures - Subject has any medical condition that might interfere with the subject’s study participation - Subject has ≥3x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Percent change in partial seizure frequency per week from Baseline to Visit 6 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. From Baseline (Week 0) to Visit 6 (up to Week 6) |
|
E.5.2 | Secondary end point(s) |
1. Percent change in partial seizure frequency per week from Baseline to Visit 4 2. Percent change in partial seizure frequency per week from Baseline to Visit 5 3. Percent change in partial seizure frequency per week on adjunctive therapy 4. Percent change in partial seizure frequency per week grouped into 6 categories on adjunctive therapy 5. Percent change in partial seizure frequency per week on monotherapy 6. Percent change in partial seizure frequency per week grouped into 6 categories on monotherapy 7. Incidence of treatment-emergent adverse events (TEAEs) during the First Period 8. Incidence of treatment-emergent serious adverse events (SAEs) during the First Period 9. Incidence of TEAEs leading to discontinuation from study medication during the First Period 10. Incidence of TEAEs during the Combined First and Second Period 11. Incidence of treatment-emergent SAEs during the Combined First and Second Period 12. Incidence of TEAEs leading to discontinuation from study medication during the Combined First and Second Period |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. From Baseline (Week 0) to Visit 4 (up to Week 2) 2. From Baseline (Week 0) to Visit 5 (up to Week 4) 3.; 4.; 5; 6. From Baseline (Week 0) for each Visit (up to Week 312) 7.; 8.; 9. From Baseline (Week 0) to Visit 6 (up to Week 6) 10.; 11.; 12. From Baseline (Week 0) to the End of Safety Follow-up (up to Week 314) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 3 |